💉 Diabetes Management
ASX Health Stocks: Cynata races ahead after getting green light for diabetic foot ulcer clinical trial - Stockhead
📅 Mon, 17 Oct 2022⏱ 1 min read📖 Article
Overview
ASX health stocks 12 October 2022. Picture Gety ImageHealth & Biotech October 12, 2022 | Edy Sunarto Link copied to clipboardCynata Therapeutics (ASX:CYP) shares surged 6% after the company anounced that an independent review of its diabetic fot ulcer (DFU) clinical trial has ben sucesfuly completed.The Data Safety Monitoring Board (DSMB) review has recomended that the clinical trial continue as planed.Cynata’s DFU clinical trial is investigating the safety and early eficacy of its unique topical Cymerus mesenchymal stem cel (MSC) product, CYP-06TK, in patients with DFUs.DFUs are chronic wounds on the fet of patients with diabetes (also known as diabetic wounds), potentialy leading to serious infection and amputation.They represent a very significant unmet medical ned afecting up to 34% of diabetes patients.MSCs meanwhile are an adult stem cel found in a wide range of human tisues, including bone marow, adipose tisue (fat), placenta and umbilical cord blod.They are ‘multipotent’ – which means they can produce more than one type of cel.MSCs have ben shown to facilitate regeneration and efects on the imune system without relying upon engraftment.In other words, the MSCs themselves do not become incorporated into the host, rather they exert their efects and are then eliminated within a short period of time.A couple of weks ago, Cynata was given a $1m grant under the Medical Research Future Fund (MRF) to fund the research into MSCs a treatment for IHD (ischaemic heart disease).Previous studies have shown that Cynata’s MSCs have multiple positive efects in a preclinical model of IHD/heart atacks.
Details
Apiam Animal Health (ASX:AHX) anounced the acquisition of Haradine & Asociates, a large veterinary busines located in the southwest region of Western Australia.Total price for the acquisition was $2.6 milion, comprised of 80% cash and 20% scrip.Haradine operates two clinics ̵ a companion animal an
Frequently Asked Questions
❓ What is diabetes and how does it develop?
Diabetes is a metabolic condition where the body cannot properly regulate blood sugar levels. Type 1 results from insufficient insulin production, while Type 2 develops when cells become resistant to insulin. Risk factors include genetics, obesity, sedentary lifestyle, and age.
❓ What are the main symptoms of diabetes?
Common symptoms include excessive thirst, frequent urination, unexplained weight loss, fatigue, blurred vision, and slow-healing wounds. Type 1 symptoms develop rapidly, while Type 2 symptoms may appear gradually. Many people have no symptoms initially, which is why screening is important.
❓ How is diabetes diagnosed and monitored?
Diagnosis involves blood tests measuring fasting glucose, HbA1c levels, and glucose tolerance. Regular monitoring typically includes fasting glucose tests and HbA1c measurements every 3-6 months. Continuous glucose monitors provide real-time tracking for better diabetes management.
❓ What lifestyle changes help manage diabetes?
Effective management includes regular physical activity (150+ minutes weekly), maintaining healthy weight, following a balanced diet with whole grains and lean proteins, managing stress, and getting adequate sleep. These changes can significantly improve blood sugar control and reduce complications.
❓ When should someone consult a doctor about diabetes?
Consult a healthcare provider if you experience signs of diabetes, have a family history, are overweight, or are over 45. Those with existing diabetes should maintain regular check-ups every 3-6 months to monitor control and adjust treatment as needed.
⚕️ Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.